Quralis Announces Topline Data From Its Phase 1 Clinical Trial Of QRL-101 Evaluating Biomarkers Of ALS And Epilepsy In Healthy Volunteers
Results demonstrated statistically significant effects on biomarkers that predict ALS disease progression and severity Evidence of brain pe ...
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival AdvantageSALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene ...